Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs... see more

Recent & Breaking News (NDAQ:VERU)

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

GlobeNewswire March 8, 2021

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire March 1, 2021

Veru Submits New Drug Application for Proprietary TADFIN for BPH

GlobeNewswire February 23, 2021

Veru Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 17, 2021

Veru Announces Proposed Public Offering of Common Stock

GlobeNewswire February 17, 2021

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter

GlobeNewswire February 10, 2021

Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

GlobeNewswire February 8, 2021

Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th

GlobeNewswire January 27, 2021

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies

GlobeNewswire January 19, 2021

Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021

GlobeNewswire January 4, 2021

Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

GlobeNewswire December 14, 2020

VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer

GlobeNewswire December 14, 2020

Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer

GlobeNewswire December 9, 2020

Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results

GlobeNewswire December 9, 2020

Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th

GlobeNewswire November 23, 2020

Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer

GlobeNewswire September 29, 2020

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

GlobeNewswire September 18, 2020

Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences

GlobeNewswire September 9, 2020

Veru Extends Agreement with Roman for Veru's Premature Ejaculation Treatment Product

GlobeNewswire August 18, 2020